FinscoFinsco

Adaptive Biotechnologies (US.ADPT)

Capital Allocation Audit · Period: 2012 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ADPT · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion-→
ROE-41.9%↓
Cash Conversion-→
D/E Ratio2.87↓
Gross Margin72.7%↑
US.ADPT (Adaptive Biotechnologies) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion        -    →
ROE              -41.9%    ↓
Cash Conversion       -    →
D/E Ratio          2.87    ↓
Gross Margin      72.7%    ↑
Key Metrics
US.ADPT (Adaptive Biotechnologies) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion - →
ROE -41.9% ↓
Cash Conversion - →
D/E Ratio 2.87 ↓
Gross Margin 72.7% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies